• Source : Press Release
  • Date : 2021-11-24
  • Event type : Phase 3
  • Companies : Merck KGaA

Solasia's Partner, Isofol Receives FDA Fast Track Designation for Arfolitixorin (SP-05) in Advanced Colorectal Cancer

Isofol Medical AB (publ) (STO: ISOFOL), Solasia's partner announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for the development of the drug candidate arfolitixorin (SP-05), the stabilized and biologically active pure form of folate ([6R]- MTHF), for treatment of patients with metastatic colorectal cancer (mCRC). For more information, please refer to the Isofol's website. Link